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Statins, which are known as cholesterol-lowering drugs, have several additional effects including the 
enhancement of bone formation and the stimulation of smooth muscle cell proliferation. In this study, we 
investigated the signal pathway of simvastatin operating in C2C12 myoblast cells. Myotube formation of 
C2C12 cells was efficiently blocked by 1 M simvastatin, and mevalonic acid was able to cancel this 
effect. Geranylgeranyl pyrophosphate restored the myotube formation, whereas farnesyl pyrophosphate 
did not. These findings demonstrate that the Rho family, such as Rho, Rac and Cdc42, occurring 
downstream of geranylgeranyl pyrophosphate in the mevalonic acid pathway, was involved in the 
simvastatin-mediated blockage of myotube formation. An inhibitor of Rho kinase did not influence the 
myotube formation; whereas an inhibitor of Rac blocked this process. Taken together, we conclude that 
the differentiation of C2C12 cells into myotubes was blocked by simvastatin through the pathway 




Statins function as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, one of 
the enzymes involved in the synthesis of cholesterol. They are commonly prescribed for 
hypercholesterolemia, and greatly reduce cardiovascular-related morbidity and mortality (Hebert et al. 
1997; Pedersen 1999; Maron et al. 2000; Vaughan et al. 2000). Moreover, statins have multipotent effects 
beyond their cholesterol-lowering properties, such as the decrease in platelet aggregation, thrombus 
deposition (Lacoste et al. 1995), promotion of angiogenesis (Kureishi et al. 2000), decrease in b-amyloid 
peptide related to Alzheimer’s disease (Fassbender et al. 2001; Kojro et al. 2001; Sidera et al. 2005), 
suppression of T lymphocyte activation (Kwak et al. 2000), induction of apoptosis (Guijarro et al. 1998; 
Li et al. 2002), inhibition of valve calcification (Osman et al. 2006a, b), and enhancement of bone 
formation (Mundy et al. 1999; Maeda et al. 2004).  
 It had been suspected that statins have a positive effect on bone formation, because statin-administered 
senior patients tended to have a reduced incidence of osteoporosis. Later, this observation was confirmed 
by in vitro studies demonstrating that statins enhanced bone formation by osteogenic cells (Mundy et al. 
1999). This effect was mainly attributed to the increased expression of bone morphogenetic protein 2 
(BMP2) (Mundy et al. 1999; Sugiyama et al. 2000; Ruiz-Gaspa et al. 2007). Based on the results on 
osteogenic cells, it became clear that the inactivation of Rho is involved in statin-induced BMP2 
expression. Because Rho suppresses the BMP2 expression, statins are likely to increase the expression of 
BMP2 as a result of the inactivation of Rho (Ohnaka et al. 2001).  
 BMP2 is one of the transforming growth factor- superfamily members and strongly induces osteogenic 
differentiation in several types of cells. In osteogenic cells, BMP2 increases an alkaline phosphatase 
(ALP) activity, stimulates osteocalcin production, and finally enhances mineralization. Moreover, osseous 
tissue is induced by BMP implanted under rat skin or in the muscle (Wozney et al. 1988). Furthermore, 
BMP2 increases ALP activity in non-osteogenic cells, such as C2C12 and C3H10T1/2 cells (Katagiri et al. 
1990, 1994), and causes them to change from myoblastic and fibroblastic cells, respectively, to osteogenic 
cells. Osteogenic differentiation in bone marrow stromal cells is also enhanced by BMP. BMP leads bone 
marrow stromal cells to differentiate into osteoblastic cells and blocks the adipocyte differentiation of 
ST2 cells induced by hydrocortisone and indomethacin (Song et al. 2003). Statins also possess this 
osteoblastic differentiationpromoting effect on bone marrow stromal cells. For instance, the adipocyte 
differentiation of D1, an established bone marrow stromal cell, has been reported to be suppressed by 
lovastatin (Li et al. 2003). 
 In osteoblastic cells, statins have been reported to block mevalonic acid production by inhibiting 
HMG-CoA reductase activity, leading to inactivation of Rho, which is located downstream of mevalonic 
acid, and a subsequent increase in BMP2 production (Mundy et al. 1999; Sugiyama et al. 2000; 
Ruiz-Gaspa et al. 2007). In addition to osteoblastic cells, the stimulation of BMP2 expression by statins 
has been reported on bone marrow stromal cells (Song et al. 2003) and ES cells (Phillips et al. 2001). 
However, there have so far been few reports describing the signals of statins in myoblast cells (Matzno et 
al. 2005; Madonna et al. 2005; Ogura et al. 2007). Rhabdomyolysis, which is muscular cell collapse 
accompanied by the release of myoglobin, is a serious side effect of statins (Sica and Gehr 2002; Jamal et 
al. 2004). In addition, an inhibitory effect of statins on proliferation of smooth muscle cell has been 
reported (Corsini et al. 1998). Hence, it is of importance to evaluate the effect of statins on muscle cells 
and elucidate the mechanism of their action. 
 The goal of the present study was to elucidate the signal pathway, by which statins inhibit myotube 
formation in C2C12 myoblast cells. We examined the effect of simvastatin on C2C12 cells, which 
develop myotubes by cell fusion during cultivation after confluence (Yaffe and Saxel 1977; Yamasaki et 
al. 1999). We demonstrate that simvastatin suppressed the myotube formation of C2C12 cells by acting 
through the Rac pathway. 
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Simvastatin was purchased from Calbiochem (San Diego, CA, USA). Mevalonic acid (MVA), 
geranylgeranyl pyrophosphoric acid (GGPP), and feranyl pyrophosphoric acid (FPP) were purchased 
from Sigma Chemical Co. (St. Louis, MO, USA). Recombinant human BMP2 and Y27632 were obtained 





C2C12 mouse myoblast cells (obtained from RIKEN cell bank, Tsukuba, Japan) were plated in 12-well 
plates at a concentration of 1 x 104 cells/cm2 and cultured in Dulbecco’s Modified Eagle’s Medium 
(Sigma Chemical Co.) supplied with 10% fetal bovine serum (FBS: Biological Industries, Kibbutz bet 
Haemek, Israel), 50 units/ml penicillin, and 50 g/ml streptomycin (Life Technology, Inc., Grand Island, 
NY, USA). After reaching confluence (defined as day 0), the cells were cultured in Minimum Essential 
Medium alpha modification (Sigma Chemical Co.) supplemented with 10% FBS, 50 units/ml penicillin, 
50 g/ml streptomycin, 80 g/ml L-ascorbic acid phosphate magnesium salt (Wako Pure Chemical 
Industry), and 5 mM b-glycerophosphate (Kanto Chemical Co., Tokyo, Japan). The medium was changed 
every 2–3 days. On day 0, simvastatin (1 M), MVA (1 mM), GGPP (8.9 M), FPP (9.2 M), NSC23766 
(100 M) or Y27632 (60 M) or their combinations were added. The vehicle (dimethyl sulfoxide) was 
added as a control. 
 
Evaluation of myotube formation 
 
C2C12 cells cultured in 12-well plates in the absence or presence of chemical reagents for up to 11 days 
were washed three times with Dulbecco’s phosphate-buffered saline (Sigma Chemical Co.) at 4C, fixed 
with 4% formaldehyde containing 85 mM CaCl2 for 15 min, and then stained with 0.05% toluidine blue 
for 30 min. The myotubes in nine fields of vision (1.05 x 0.71 mm) were counted and expressed as the 
number ± SEM per 1 mm2. 
 
Quantitative RT-PCR analysis 
 
CellularRNAwas isolated from C2C12 cells by using Isogen reagent (Nippon Gene Co., Tokyo, Japan), 
and cDNA was prepared from 2.5 g of RNA with reverse transcriptase (Takara, Shiga, Japan) in a 
reaction mixture (20 l) containing 0.5 mM deoxynucleotide triphosphates and 0.2 g of oligo dT (Life 
Technology Inc.). The expression level of myogenin mRNA was quantified by real-time RT-PCR 
(Mx3005P Real-time PCR system, Stratagene, La Jolla, CA, USA). The reaction mixture (25 l) 
contained 0.5 l of cDNA and 0.4 M primers, and the reaction was performedwith the Full Velocity 
SYBR Green QPCR system. The primer set used for the amplification of mouse myogenin was 
5’-CATCCAGTACATTGAGCGCCTA-3’ (sense) and 5’-GAGCAAATGATCTCCTGGGTTG-3’ 
(antisense) (Wedhas et al. 2005). The reaction was performed as follows: incubation at 94C for 10 min to 
activate the polymerase followed by 40 cycles of amplification. Each cycle consisted of denaturation at 
94C for 20 s and an annealing/extension at 60C for 1 min. Reactions were carried out in triplicate. The 
relative expression of myogenin mRNA was normalized by the level of mouse GAPDH mRNA. 
 
Alkaline phosphatase activity 
 
Alkaline phosphatase activity was determined according to the protocol described previously (Baba 2000). 
In brief, the cells were sonicated in solubilization buffer (10 mM Tris–HCl, pH 7.4, containing 0.1% 
Triton X-100) and centrifuged at 12,000g for 20 min. The supernatant was used for the measurement of 
the ALP activity. The reaction mixture (0.15 ml) comprising 4 mM p-nitrophenyl phosphate and 5 mM 
MgCl2 in 50 mM carbonate buffer (pH 10) was incubated at room temperature for 6 min, mixed with 50 
5 
l of 2 M NaOH, and then, absorbance at 405 nm was determined. One unit was defined as the quantity 
of ALP that produced 1 mg of p-nitrophenol in 1 h. 
 
Protein concentration 
Protein concentrations were determined with a BCA protein assay kit (Pierce Chemical Co., Rockford, IL, 
USA) according to the manufacturer’s instruction. Bovine serum albumin was used as a reference. 
 
Statistical analysis 





Effects of BMP2 and simvastatin on differentiation of C2C12 cells 
 
 It has been reported that statins enhance the expression of BMP2 in osteoblast cells. Because BMP2 
strongly induces the differentiation of several types of cells including C2C12 myoblastic cells into 
osteoblastic cells, it seemed reasonable to speculate that statins would also induce the differentiation of 
C2C12 cells into osteoblastic cells. When C2C12 cells were successively cultured after confluence, 
myotube formation was recognized on day 2, and the number of myotubes formed consistently increased 
until day 11 (Fig. 1A). In contrast, myotubes were not observed in the cultures treated with 3 nM BMP2 
or 1 M simvastatin even on day 11 (Fig. 1A). 
 The ALP activity was constant for 11 days in the control. In contrast, the activity significantly increased 
in the BMP2 group until day 8, on which it was 14-fold higher than that of the control group. The ALP 
activity of the simvastatin group increased 2.7-fold on day 8 in comparison with the control level, i.e., 
only one-fifth of that of the BMP group (Fig. 1B). 
 The expression level of the mRNA of myogenin, a marker protein of myoblasts, was quantified by 
real-time RT-PCR (Fig. 1C). On day 3, 38.5% suppression of the myogenin expression was achieved by 
the addition of BMP2. In contrast, simvastatin did not affect the mRNA level. Taken together, these data 
indicated that BMP2 blocked the myotube formation, increased the ALP activity, and reduced the 
myogenin mRNA expression, thus demonstrating that BMP2 modified the lineage of C2C12 cells from 
the myogenic to the osteoblastic cells as reported previously (Katagiri et al. 1997). However, simvastatin 
seemed to block the myotube formation in a manner distinct from that of BMP2, because the expression 
of MyoD mRNA (data not shown) and myogenin mRNA was not reduced by simvastatin and the ALP 
activity did not significantly increased. 
 
Mechanism on differentiation inhibition of C2C12 cells by simvastatin 
 
 It has been reported that osteoblast differentiation induced by statins is tightly associated with the 
inhibition of Rho (Ohnaka et al. 2001). In contrast, the functional mechanism of statins on myoblastic 
cells remains to be elucidated. As shown in Fig. 1, the effect of simvastatin on C2C12 cells appeared to be 
distinct from that of BMP2. This raised a question on the pathway that BMP2 mediates the inhibition of 
Rho in C2C12 cells. To address this issue, we first examined whether simvastatin inhibited myotube 
formation via the mevalonic acid pathway. That is, 1 mM mevalonic acid was added to the C2C12 culture 
in the presence or absence of 1 M simvastatin (Fig. 2). Myotube formation efficiently inhibited by 
simvastatin (2.2% of the control) was reversed by the addition of mevalonic acid, resulting in the increase 
up to 89.1% of the control. 
 To further elucidate its downstream events, the effects of GGPP and FPP, i.e., alternative metabolites of 
mevalonic acid in the pathway, were examined. Myotube formation was restored up to 54.1% of the 
control by the addition of 4.4 M GGPP (data not shown) and 85.1% by 8.9 M GGPP, although GGPP 
itself did not further enhance the myotube formation (Fig. 3A). In contrast, 9.2 M FPP could not restore 
the formation (Fig. 3B). This finding indicated that the effect of simvastatin was mediated by GGPP. 
 Members of the Rho family are prenylated by GGPP. In order to compare with simvastatin signaling in 
osteoblastic cells where Rho-kinase activity was suppressed by statins, we examined the effects of Rho 
kinase inhibitor, Y27632. Sixty M Y27632, which was sufficient for kinase inhibition (Li et al. 2002; 
Tuner et al. 2007), had no inhibitory effect on myotube formation (Fig. 4A). This finding further 
suggested that the signal pathway in myoblastic cells was distinct from that in osteoblastic cells. 
 To evaluate the signal pathway downstream of GGPP, NSC23766, an inhibitor of the pathway mediated 
by Rac (another member of Rho family) was tested. As a result, myotube formation was 67% suppressed 
by the addition of 50 M NSC23766 (data not shown), and 100 M NSC23766 shut down the myotube 
formation to 3.1% of the control (Fig. 4B). These findings demonstrated that the simvastatin signaling 




 Statins are HMG-CoA reductase inhibitors, which strongly block the conversion of HMG-CoA to 
mevalonic acid. In osteoblastic cells, statins block mevalonic acid production and reduce the activity of 
Rho located downstream of the mevalonic acid of this pathway, thus inducing BMP2 production (Mundy 
et al. 1999; Sugiyama et al. 2000; Ruiz-Gaspa et al. 2007). In addition to osteoblastic cells, bone marrow 
stromal cells (Song et al. 2003) and ES cells (Phillips et al. 2001) have been reported to be stimulated by 
statins to express BMP2. However, there have so far been few reports describing the signals of statins in 
myoblast cells. 
 The present study confirmed that BMP2 diverted the lineage of C2C12 cells from myoblastic cells into 
osteoblastic cells. In contrast, simvastatin neither significantly increased the ALP activity nor suppressed 
the myogenin mRNA expression, although it did inhibit the myotube formation of the cells. These 
findings suggested that the signal pathway of simvastatin in C2C12 cells was not associated with the 
BMP2 expression. We further demonstrated that simvastatin utilized the mevalonic acid pathway to block 
myotube formation. Moreover, GGPP, one of the intermediate metabolites of the pathway, selectively 
restored the myotube formation. The events further downstream of GGPP are known to be mediated by 
Rho family proteins, which are small G proteins, such as Rho, Rac and Cdc42 (Zhang and Casey 1996). 
Finally, NSC23766 specifically interfered with myotube formation, but Y27632 could not, which showed 
that the simvastatin signal was passed along by Rac, not Rho. This finding convinced that the functional 
mechanism of statins in C2C12 cells was not associated with BMP2, of which expression was suppressed 
by Rho (Fig. 5). 
 There might be a possibility that the signal of simvastatin in C2C12 is mediated by Cdc42, the third 
major member of Rho-family. Because the present study focused on the discrimination of the effects and 
the pathways between simvastatin and BMP2, we did not investigate the role of Cdc42 in the simvastatin 
pathway. The role of Cdc42 and the downstream of Rac should be evaluated on C2C12 in future studies. 
 Figure 5 summarizes the mevalonic acid pathway in consideration with the simvastatin signal in C2C12 
cells. GGPP can be converted from FPP by trans-prenyl transferase in the mevalonic acid pathway 
(broken arrow), whereas this reaction seemed not to occur or proceeded very slowly in C2C12 cells, 
because the effects of GGPP and FPP were different. Similarly, it was reported that PDGF-stimulated 
migration of osteoblasts was blocked by simvastatin and that the blockage was reversed by GGPP, but not 
by FPP (Fukuyama et al. 2004). The suppression of smooth muscle-cell proliferation by simvastatin was 
blocked by GGPP, but not by FPP (Takeda et al. 2006). 
 Recently, Ogura et al. (2007) reported the simvastatin signaling in C2C12 cells. They cultured the cells 
under three conditions; proliferating, differentiating, and differentiated, and insisted that the simvastatin 
functioned in anHMG-CoA reductase inhibition-independent manner, because, under the differentiating 
condition, the effect of simvastatin was not restored by mevalonic acid and GGPP. However, under the 
differentiated condition, which resembled the culture condition employed in our study, the cell viability 
was dependent on HMG-CoA reductase inhibition. This indicated that simvastatin signal was mediated 
through mevalonic acid and GGPP, although they did not further study on the subsequent pathway. 
Accordingly, their report could be compatible with our result that simvastatin signal passed through 
GGPP in C2C12 cells. 
 In this report, we found that the simvastatin signaling in myoblasts is different from that in osteoblasts. 
This finding may shed light on myopathy, side-effect of statin treatment. The suppression of myotube 
formation is concerned with Rac, whereas stimulation of bone formation is concerned with Rho. If Rac 
activity can be specifically restored by a reagent, bone formation could be stimulated by statins avoiding 
any muscle problem. 
 In conclusion, the inhibition of C2C12 cell differentiation into myotube by simvastatin was mediated 
through the mevalonic acid-GGPP-Rac pathway, distinct from the pathway mediated by mevalonic 
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Figure 1   
Inhibition of myotube formation of C2C12 cells by BMP2 and simvastatin. (A) Phase-contrast 
microscopic images of C2C12 cells cultured for 11 days in the absence (control) or presence of 3 nM 
BMP2 or 1 M simvastatin (SMV). (B) ALP activity in C2C12 cells cultured for 2, 5, 8 or 10 days in the 
absence (control) and presence of 3 nM BMP2 or 1 M simvastatin (SMV). (C) Myogenin expression in 
C2C12 on day 3 in the absence (control) and presence of 3 nM BMP2 or 1 M simvastatin (SMV) was 
measured by real-time RT-PCR as described in “Materials and methods.”  
 
Figure 2.   
Mevalonic acid canceled the inhibitory effect of simvastatin. (A) Phase-contrast microscopic images of 
C2C12 cells cultured for 4 days in the absence (control) and presence of 1 M simvastatin (SMV) or 1 
M simvastatin plus 1 mM mevalonic acid (SMV+MVA). Arrows show myotubes. (B) Number of 
myotubes formed by C2C12 cells cultured for 4 days in the absence of additives (control), presence of 1 
M simvastatin (SMV), 1 mM mevalonic acid (MVA) or their combination (SMV+MVA). Bar= 0.2 mm.   
 
Figure 3.   
Differential effect of GGPP and FPP on simvastatin-induced myotube formation by C2C12 cells. (A) 
C2C12 cells were cultured in the absence of additives (control), presence of 1 M simvastatin (SMV), 
8.9 µM GGPP or their combination (SMV+GGPP).  Histological images on day 4 are shown (left), and 
the number of myotubes was evaluated (right). (B) C2C12 cells were cultured in the absence of additives 
(control), presence of 1 M simvastatin (SMV), 9.2 µM FPP or their combination (SMV+FPP).  
Histological images on day 4 are shown (left), and the number of myotubes was evaluated (right). Bar= 
0.2 mm.  
 
Figure 4 
Blockage of myotube formation by NSC23766, but not by Y27632. (A) C2C12 cells were cultured in the 
absence (control) or presence of 60 µM Y27632. Histological images on day 4 are shown (left), and the 
number of myotubes was evaluated (right). (B) C2C12 cells were cultured in the absence (control) or 
presence of 100 µM NSC23766. Histological images on day 3 are shown (left), and the number of 
myotubes was evaluated (right). Bar= 0.2 mm.  
 
Figure 5.  
Metabolism of mevalonic acid pathway in C2C12 cells. The metabolic pathway of mevalonic acid is 
schematically illustrated, as shown previously [Horiuchi and Maeda 2006].  The major metabolic route 
in C2C12 cells revealed in the present study is represented by the bold arrows.  A broken arrow shows a 
minor or negligible pathway (see text).  
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